scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companayâs pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
äŒæ¥ã³ãŒãSCPH
äŒç€ŸåscPharmaceuticals Inc
äžå Žæ¥Nov 17, 2017
æé«çµå¶è²¬ä»»è
ãCEOãMr. John H. Tucker
åŸæ¥å¡æ°162
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Nov 17
æ¬ç€Ÿæåšå°25 Burlington Mall Road, Suite 203
éœåžBURLINGTON
蚌åžååŒæNASDAQ Global Select Consolidated
åœUnited States of America
éµäŸ¿çªå·01803
é»è©±çªå·16175170730
ãŠã§ããµã€ãhttps://www.scpharmaceuticals.com/
äŒæ¥ã³ãŒãSCPH
äžå Žæ¥Nov 17, 2017
æé«çµå¶è²¬ä»»è
ãCEOãMr. John H. Tucker
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã